Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta‐Analysis

ABSTRACT Background Type 2 diabetes mellitus (T2DM) often requires combination therapy when metformin alone becomes insufficient. Empagliflozin (SGLT2 inhibitor) and sitagliptin (DPP‐4 inhibitor) are commonly used add‐on agents with differing metabolic profiles. This systematic review and meta‐analy...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Saad Ashraf, Muhammad Burhan, Sara Sarwar, Ahila Ali, Aiza Ahsan, Shahzad Ashraf, Hammad Javaid, Hamza Irfan, Muhammad Hamza Naseer Awan, Ajeet Singh, Biruk Demisse Ayalew
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2026-05-01
Serie:	Endocrinology, Diabetes & Metabolism
Soggetti:	cardiometabolic outcomes empagliflozin meta‐analysis metformin sitagliptin type 2 diabetes
Accesso online:	https://doi.org/10.1002/edm2.70238
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!